BioMedNewsBreaks

TuesdayOct 20, 2026 3:17 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Scales GelrinC Manufacturing Amidst Development Progress

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel technology, designed to promote the regeneration of durable, natural-like cartilage in patients with painful knee cartilage injuries. The cell-free, off-the-shelf implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, while the company has reported greater pain improvement than traditional microfracture. Regentis has treated 43 of 80 planned patients in its U.S. pivotal Phase III trial, with enrollment expected to conclude around the end of 2026, and is preparing for…

Continue Reading

TuesdayOct 20, 2026 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present AI-Enabled Drug Discovery Keynote at 22nd Drug Discovery Strategic Summit

Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. Saund will discuss the company's proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and…

Continue Reading

MondayOct 19, 2026 3:21 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial Results

Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article highlights findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with…

Continue Reading

MondayOct 19, 2026 11:07 am

BioMedNewsBreaks — ECGI Holdings Inc. (OTC: ECGI) Highlights Avanta Acquisition and Growing Opportunities in $5.3 Trillion U.S. Healthcare Market 

ECGI Holdings (OTC: ECGI) is featured in an AINewsWire editorial examining the shift toward preventive, coordinated healthcare and the growing role of artificial intelligence in improving patient outcomes and managing costs. The editorial highlights ECGI's acquisition of Avanta Group, a developing integrated healthcare platform encompassing Medicare Advantage insurance, management services, AI-enabled technology, consumer health and healthcare infrastructure. The acquisition positions ECGI to pursue opportunities in a U.S. healthcare market that reached $5.3 trillion in 2024, with Medicare Advantage payments projected to total $574 billion in 2026. The editorial also discusses the potential for integrated technology and care coordination to improve…

Continue Reading

FridayOct 16, 2026 3:40 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Highlights Insider Buying Alongside Its Integrated Healthcare Technology Strategy

Recent SEC Form 4 filings disclosed open-market purchases of Nano-X Imaging Ltd.’s (NASDAQ: NNOX) (“Nanox”) ordinary shares by CEO Erez Meltzer and Board Director Dan Suesskind, adding to purchases reported in recent months by Meltzer, Suesskind and Board Director Nogah Keinan. The transactions reflect share purchases made directly in the open market by the company’s senior leadership and board members, with additional details available in the respective SEC filings. This comes as Nanox continues to advance its integrated medical imaging and healthcare services platform, which combines proprietary digital X-ray technology, AI-powered imaging analytics, cloud-based software, remote radiology services and healthcare…

Continue Reading

FridayOct 16, 2026 2:18 pm

BioMedNewsBreaks — Nanox Imaging Ltd. (NASDAQ: NNOX) Subsidiary Signs Distribution Agreement to Commercialize HealthOST in Italy

Nanox (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI commercial presence in the Italian market, leveraging Technologic experience and local market knowledge. HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis. To view the full press release, visit https://ibn.fm/y9Zro About Nanox Nanox (NASDAQ:…

Continue Reading

FridayOct 16, 2026 1:47 pm

BioMedNewsBreaks — Nanox Imaging Ltd. (NASDAQ: NNOX) Nanox.ARC X Named One of TIME Best Inventions of 2026

Nanox (NASDAQ: NNOX), a medical imaging technology company, announced that its Nanox.ARC X digital tomosynthesis system has been named one of TIME's Best Inventions of 2026. The U.S. Food and Drug Administration-cleared system captures X-ray images from multiple angles, generating up to 200 coronal images per scan to produce three-dimensional views of the body at up to 80% less radiation than computed tomography ("CT") for equivalent body parts. Designed with a smaller footprint than conventional CT systems, Nanox.ARC X operates using a standard 110-volt power outlet and features simplified installation, operator workflows and remote upgrade capabilities. The company plans to…

Continue Reading

FridayOct 16, 2026 12:30 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Aon Review Supporting Estimated Annual Healthcare Cost Savings of 2.5% to 7.2%

DarioHealth (NASDAQ: DRIO) announced results of a review conducted by the Managed Care Services Team of Aon plc evaluating the clinical and financial impact of its AI-powered chronic condition management services. Based on data and studies provided or identified by DarioHealth, Aon concluded that the evidence supports estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population, equivalent to approximately $3.8 million to $10.8 million annually for a representative population of 20,000 covered lives. Aon also estimated that management of multiple conditions and access to physicians, which were excluded from the initial calculations, could contribute an additional…

Continue Reading

ThursdayOct 15, 2026 3:48 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advances Expansion Plans with Meduvo and Zoolzy Acquisitions, Uplisting

Earth Science Tech (OTCQB: ETST), a healthcare, pharmacy, and telemedicine holding company, uplisted to the OTCQB Venture Market on Sept. 17, 2026, marking a key milestone in its fiscal 2027 growth strategy. The move follows a strong first quarter, with revenue increasing 3% to $9.0 million and net income rising 57% to $715,697, alongside acquisitions of Meduvo LLC, a compounding pharmacy, and Zoolzy LLC, a pharmaceutical distributor that expands the company’s opportunities in human therapeutics and animal health. At its Aug. 31 annual shareholder meeting, investors also approved measures supporting potential future uplisting to the Nasdaq or NYSE, the planned…

Continue Reading

WednesdayOct 14, 2026 3:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, received U.S. Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application for Lucid-MS, clearing the way for Phase 2 clinical testing of its multiple sclerosis (“MS”) candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug’s efficacy, safety and tolerability in patients with MS, with researchers assessing clinical symptoms and changes visible through brain imaging. Unlike many existing MS therapies that target the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage,…

Continue Reading